Abstract
Maytansine given in a 3-day course q3 weeks produced only five responses (3%) in 163 evaluable adults with advanced cancer. The dose schedule employed is not recommended for further study.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Drug Administration Schedule
-
Drug Evaluation
-
Female
-
Humans
-
Male
-
Maytansine / administration & dosage
-
Maytansine / adverse effects
-
Maytansine / therapeutic use*
-
Middle Aged
-
Neoplasms / drug therapy*
-
Neoplasms / pathology
-
Oxazines / therapeutic use*